Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Familial parathyroid tumours-comparison of clinical profiles between syndromes.

Journal of endocrinological investigation·2023
Same author

Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.

Journal of endocrinological investigation·2021
Same author

The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.

Journal of endocrinological investigation·2018
Same author

The role of EIF1AX in thyroid cancer tumourigenesis and progression.

Journal of endocrinological investigation·2018
Same author

JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21.

Oncogene·2017
Same author

Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.

Endocrine·2015

Related Experiment Video

Updated: Jun 19, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

J M Pita1, A Banito, B M Cavaco

  • 1Centro de Investigação de Patobiologia Molecular (CIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa 1099-023, Portugal.

British Journal of Cancer
|October 8, 2009
PubMed
Summary

Follicular variant papillary thyroid carcinomas (fvPTC) may precede poorly differentiated thyroid carcinomas (PDTC). Gene expression analysis identified UHRF1 and ITIH5 as potential therapeutic targets for aggressive thyroid tumors.

Related Experiment Videos

Last Updated: Jun 19, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Poorly differentiated thyroid carcinomas (PDTC) are aggressive and heterogeneous, potentially arising from well-differentiated tumors.
  • Understanding PDTC progression mechanisms is crucial for identifying new therapeutic targets.

Purpose of the Study:

  • To investigate genome-wide gene expression in normal and tumor thyroid tissues.
  • To elucidate mechanisms of thyroid carcinoma progression and identify therapeutic targets.

Main Methods:

  • Microarray analysis of 24 thyroid carcinomas (papillary, follicular, PDTC) and correlation with genetic alterations (RAS, BRAF, RET/PTC, PAX8-PPARG).
  • Validation of selected genes using quantitative RT-PCR in 28 independent thyroid tumors.

Main Results:

  • Gene expression similarity was observed between PDTC and follicular variant papillary thyroid carcinoma (fvPTC), especially with RAS mutations.
  • PDTC molecular signatures indicated cell proliferation, poor prognosis, spindle assembly checkpoint, and cell adhesion.
  • Gene downregulation was prominent in PDTC (86% of analyzed genes) and FTC (80%), suggesting a role in dedifferentiation.
  • UHRF1 and ITIH5 gene expression deregulation in PDTC was confirmed by RT-PCR.

Conclusions:

  • Follicular variant papillary thyroid carcinomas (fvPTC) are suggested as potential precursors to PDTC.
  • UHRF1 and ITIH5 show potential as therapeutic or prognostic markers for aggressive thyroid tumors.